Business Wire·Nov 12, 2026, 7:00 AM ET

Yarrow Bioscience Reports Third Quarter 2026 Financial Results and Provides Business Update

Enrollment is ongoing in the Phase 2a/2b DIRECTION-GD trial evaluating YB-101, a potential first-in-class anti-TSHR antibody, for patients with Graves' disease with or without thyroid eye disease.
Topline results from the Phase 2a portion of the trial are expected in the second half of 2027, while the Phase 2b portion is expected to begin enrolling patients in the first half of 2028.
Licensing partner Changchun GeneScience Pharmaceutical Co., Ltd. continues advancing YB-101 in Greater China, with data from its Phase 1 multiple ascending dose trial in thyroid eye disease anticipated in the second half of 2027.
Yarrow Bioscience completed an underwritten public offering in September 2026, raising approximately $172.5 million to strengthen its financial position for clinical development.
Cash \& cash equivalents totaled $268.9 million as of September 30, 2026, providing a runway to fund operations into 2030.
Research \& development expenses were $5.3 million, general \& administrative expenses were $5.5 million, \& the net loss for the third quarter of 2026 was $9.7 million.
Yarrow completed a merger with VYNE Therapeutics Inc. in July 2026 \& began trading on Nasdaq under the ticker symbol "YARW" following the transaction.
YB-101 has received Fast Track Designation from the FDA for its potential to treat both Graves' disease \& thyroid eye disease.